EGFR and neoplasm: Besides enhancement of CRC goblet cell differentiation, both therapeutic regimens, GFHPD or anti-EGFR antibody therapy, strongly dampened colonic PD-L1 and splenic T-cell specific PD-1 immune checkpoint expression, presumably promoting improved anti-tumor immune responses.